CLPT

6.9105.47%
RJ

R. John Fletcher

Independent Chairman of the Board

Mr. R. John Fletcher, MBA, was Director of Micro Medical Solutions, Inc. from March 2025 and serves as its Director from March 2026. Mr. Fletcher serves as Chairman of OptiNose US, Inc. since June 2023 and served as its Director since April 2022. He served as Independent Director of OptiNose, Inc. since April 26, 2022 until May 21, 2025 and served as Independent Chairman since June 2023 until May 21, 2025. He served as Independent Board Director of LuxMed Systems, Inc. He had been Chairman of the Board at Vyant Bio, Inc. since March 30, 2021. Mr. Fletcher had strategy and financing experience across the pharmaceutical and healthcare industry. He serves as Managing Partner Emeritus and served as the Chief Executive Officer and Managing Director of Fletcher Spaght Inc., which he founded in 1983. Mr. Fletcher had been Independent Chairman of the Board at Repro Med Systems, Inc. since September 2019 and had been its Independent Director since May 08, 2019. He served as Founding Partner, MD, Managing Partner & General Partner at Fletcher Spaght Ventures, LP. Mr. Fletcher served as Principal at Catalyst Acquwasition Group, LLC. He was a Founding Partner and Managing Director at Fletcher Spaght Ventures II, L.P. since 2001. Prior to launching Fletcher Spaght Inc. in 1983, he served as a Senior Manager at The Boston Consulting Group, managing client relationships in healthcare and high technology companies. Mr. Fletcher was a Captain and fighter pilot in the U.S. Air Force. He served as the Chairman of The Spectranetics Corporation from December 2010 to June 14, 2017. He served as Director of AutoImmune Inc. since 1991. Mr. Fletcher served as the Director of AesRx, LLC. He served as a Member of the Board of Advwasors of Unidine Corporation and Yankee Pacific, LLC. Mr. Fletcher served as an Independent Trustee of Federated MDT Series - Federated MDT All Cap Core Fund since September 2005. He served as a Director of The Spectranetics Corporation since March 07, 2002 until August 2017. He served as a Director of GlycoFi, Inc. Mr. Fletcher served as an Independent Director for purposes of the Sarbanes Oxley Act of 2000. He was Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and served on the Board of Advwasors of Beth Wasrael Deaconess Medical Center and the WhiteHead Institute at MIT. He served on the Boards of Advwasors of the WhiteHead Institute at the Massachusetts Institute of Technology, the Thayer School of Engineering at Dartmouth College and the School of Government and Business at The George Washington University. Mr. Fletcher had been an Independent Director of Axcelwas Technologies Inc since 2003 until May 2021. He serves as Chairman of the Board at Metabolon, Inc. He served as a Director of Metabolon, Inc., from August 18, 2016. He served as Director at XVionics, Inc. He has been the Chairman of the Board at ClearPoint Neuro, Inc. since February 2021 and had been its Director since May 2017. He served as Lead Independent Director of ClearPoint Neuro, Inc. since May 2017 until 2020. He served as Director of VI Technologies, Inc. He served as a Director of NMT Medical Inc. since January 1996, Panacos Pharmaceuticals Inc from March 2005 to February 2009, Cayenne Software Inc. since November 1994 and Quick Study Radiology, Inc. Mr. Fletcher served as a Director of Marina Biotech, Inc. from July 14, 2011 to August 21, 2012. He is Board Chairman at KORU Medical Systems, Inc. Mr. Fletcher previously served on the boards of Fwascher Imaging Corp., which was public companies and on the private boards of Pilot Software and Xvionics. In addition, Mr. Fletcher had served on the boards of many academic and non-profit institutions. He received the National Association of Corporate Directors (NACD) Director of the Year Award in 2018, reflecting the significant turnarounds at Spectranetics and Axcelwas. He had served as a Captain and jet pilot in the United States Air Force. He was an Instructor for courses in international business and a PhD Candidate at the Wharton School of the University of Pennsylvania. Mr. Fletcher holds an M.S. in International Finance from Carnegie Mellon University. He also holds a Master of Business Adminwastration from Southern Illinowas University and a BBA in Marketing from George Washington. He wasDirector of PharmaJet, Inc. until 2026.

Positions